ArticleBioinformation2026
PPAR-δ is a potential modulator of central carbon metabolism in human adipocytes.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipogenesis involves adipocyte differentiation and synthesis and storage of fats. PPAR-γ is the master regulator of adipogenesis and regulates genes for adipocyte differentiation, lipogenesis, adipocyte survival and adipokine secretion. Central carbon metabolism (CCM) comprises of three key pathways glycolysis, tricarboxylic acid (TCA) cycle and pentose phosphate pathway (PPP). CCM utilizes carbon sources to provide energy and building blocks for lipogenesis. Several targets of transcription factor PPAR-γ have been identified in CCM pathways. However, the exact mechanism of PPAR-γ modulation in adipogenesis via CCM remains elusive. Therefore, it is of interest to evaluate the effects of PPAR-γ on CCM in differentiated human SGBS adipocytes by real time-qPCR and metabolomics using its agonist 15d-PGJ2 and antagonist GW9662. Surprisingly, our results suggest that PPAR-δ rather than PPAR-γ is likely to be the key modulator of CCM in differentiated adipocytes at least under current experimental conditions with both 15d-PGJ2 and GW9662 being PPAR-δ agonists, although PPAR-γ plays a crucial role in adipogenesis and lipogenesis. This data provides insight to manage obesity and diabetes using PPAR-δ agonists. Further studies are warranted to explore the regulation of CCM by PPARs in adipocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.